{"entity":{"type":"insider","cik":"0001276986","url":"/insider/0001276986","json_url":"/insider/0001276986.json","name":"THREE ARCH ASSOCIATES IV LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":5,"first":"2011-02-18","last":"2014-11-20","span_basis":"filed_date"},"name_variants":[{"name":"THREE ARCH ASSOCIATES IV LP","source":"filing","n_filings":5,"first_seen":"2011-02-18","last_seen":"2014-11-20"}],"transactions":[{"id":7087002,"accession":"0001181431-14-036963","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-14-036963","line_url":"/filing/0001181431-14-036963","is_derivative":false,"issuer_cik":"0001190472","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001190472","owner_cik":null,"owner_name":"THREE ARCH ASSOCIATES IV LP; Three Arch Management IV, L.L.C.; JAEGER WILFRED E; THREE ARCH PARTNERS IV LP; WAN MARK A","owner_display_name":"THREE ARCH ASSOCIATES IV LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250000.0,"shares_display":"250,000","price_per_share":12.29,"price_display":"12.29","price_state":"stated","total_value":3072500.0,"total_display":"3,072,500.00","total_whole":"3,072,500","shares_owned_after":557126.0,"shares_owned_after_display":"557,126","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-11-18","filed_date":"2014-11-20","scope":"insider","n_lines":2},{"id":6788558,"accession":"0001209191-14-012994","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-14-012994","line_url":"/filing/0001209191-14-012994","is_derivative":false,"issuer_cik":"0001190472","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001190472","owner_cik":null,"owner_name":"THREE ARCH PARTNERS IV LP; WAN MARK A; JAEGER WILFRED E; Three Arch Management IV, L.L.C.; THREE ARCH ASSOCIATES IV LP","owner_display_name":"THREE ARCH PARTNERS IV LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":103500.0,"shares_display":"103,500","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":1449000.0,"total_display":"1,449,000.00","total_whole":"1,449,000","shares_owned_after":801726.0,"shares_owned_after_display":"801,726","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-02-19","filed_date":"2014-02-21","scope":"insider","n_lines":2},{"id":2976072,"accession":"0001181431-12-063710","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-12-063710","line_url":"/filing/0001181431-12-063710","is_derivative":false,"issuer_cik":"0001113520","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001113520","owner_cik":null,"owner_name":"JAEGER WILFRED E; THREE ARCH PARTNERS IV LP; THREE ARCH ASSOCIATES IV LP; THREE ARCH ASSOCIATES III LP; WAN MARK A; THREE ARCH PARTNERS III LP","owner_display_name":"JAEGER WILFRED E","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2416918.0,"shares_display":"2,416,918","price_per_share":3.31,"price_display":"3.31","price_state":"stated","total_value":7999998.58,"total_display":"7,999,998.58","total_whole":"7,999,999","shares_owned_after":6323534.0,"shares_owned_after_display":"6,323,534","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-12-07","filed_date":"2012-12-11","scope":"insider","n_lines":2},{"id":9252632,"accession":"0001181431-12-035046","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-12-035046","line_url":"/filing/0001181431-12-035046","is_derivative":false,"issuer_cik":"0001113520","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001113520","owner_cik":null,"owner_name":"JAEGER WILFRED E; THREE ARCH ASSOCIATES III LP; THREE ARCH ASSOCIATES IV LP; THREE ARCH PARTNERS III LP; THREE ARCH PARTNERS IV LP; WAN MARK A","owner_display_name":"JAEGER WILFRED E","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":284698.0,"shares_display":"284,698","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":967973.2,"total_display":"967,973.20","total_whole":"967,973","shares_owned_after":3704712.0,"shares_owned_after_display":"3,704,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-29","filed_date":"2012-06-06","scope":"insider","n_lines":4},{"id":9014598,"accession":"0001181431-11-011594","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001181431-11-011594","line_url":"/filing/0001181431-11-011594","is_derivative":false,"issuer_cik":"0001190472","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001190472","owner_cik":null,"owner_name":"JAEGER WILFRED E; WAN MARK A; Three Arch Management IV, L.L.C.; THREE ARCH PARTNERS IV LP; THREE ARCH ASSOCIATES IV LP","owner_display_name":"JAEGER WILFRED E","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1289790.0,"shares_display":"1,289,790","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":6448950.0,"total_display":"6,448,950.00","total_whole":"6,448,950","shares_owned_after":3749918.0,"shares_owned_after_display":"3,749,918","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-16","filed_date":"2011-02-18","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Ten percent owner","n_filings":2,"first_seen":"2014-02-21","last_seen":"2014-11-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"ACELRX PHARMACEUTICALS INC","url":"/issuer/0001427925","role":"Ten percent owner","n_filings":3,"first_seen":"2011-02-18","last_seen":"2012-12-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001276986","retrieved_at":"2026-08-23T13:08:14+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}